DiaMedica Therapeutics In...

3.50
-0.18 (-4.89%)
At close: Apr 04, 2025, 12:38 PM
-4.89%
Bid 3.43
Market Cap 149.99M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -0.6
PE Ratio (ttm) -5.83
Forward PE -7.53
Analyst Buy
Ask 3.5
Volume 80,838
Avg. Volume (20D) 89,639
Open 3.57
Previous Close 3.68
Day's Range 3.35 - 3.59
52-Week Range 2.14 - 6.82
Beta 1.52

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 3, 2012
Employees 27
Stock Exchange NASDAQ
Ticker Symbol DMAC
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for DMAC stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 128.57% from the latest price.

Stock Forecasts
2 weeks ago
-13.02%
DiaMedica Therapeutics shares are trading lower fo... Unlock content with Pro Subscription
9 months ago
+30.97%
DiaMedica Therapeutics shares are trading higher. The company announced a $11.8 million private placement and will issue 4.720 million shares at $2.50 per share.